Limbix has developed SparkRx digital therapeutic for the treatment of depression symptoms. Credit: Kmpzzz / Shutterstock.com.

Mental health and non-drug digital treatments provider Big Health has acquired digital therapeutic developer Limbix for an undisclosed sum.

Established in 2016, Limbix is claimed to have developed the first evidence-based digital therapeutic for teens and young adults with depression symptoms.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Through its Series A funding round, the company raised $30m and developed a research-based pipeline of adolescent products.

Limbix has developed a digital therapeutic called SparkRx to provide a neurobehavioral intervention (cognitive behavioural therapy (CBT) – behavioural activation) for patients aged between 13 and 22 years as an adjunct treatment for depression symptoms.

Supported by trial data showing a clinically meaningful reduction in depression symptoms, the self-guided CBT-based treatment is intended to teach skills such as mindfulness, problem-solving, behavioural activation and mood tracking.

See Also:

The US Food and Drug Administration has not granted clearance or approval for SparkRx.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Big Health CEO and executive chairman Arun Gupta said: “We must continue to rise to the challenge of the mental health crisis – our acquisition of Limbix is a strategic milestone in advancing our mission to help millions back to good mental health.

“Our portfolio of evidence-based, clinically validated digital treatments will enable a record number of adult and adolescent patients to get immediate access to safe and effective non-drug options.”

Big Health provides a number of mental health treatments and therapies, including the Sleepio and Daylight programmes for insomnia and anxiety treatments, respectively.